Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 751 - 775 of 15016 in total

Raltegravir

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Approved
Matched Description: … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase …
Matched Categories: … lamivudine and raltegravir …

Hypromellose

Hypromellose, or hydroxypropyl methylcellulose (HPMC) , is a semisynthetic, inert, and viscoelastic polymer that forms a colloid solution when dissolved in water. It acts as a thickening agent, coating polymer, bioadhesive, solubility enhancer in solid dispersions, and binder in the process of granulation and in modified release formulations . It...
Approved
Matched Description: … binder in the process of granulation and in modified release formulations [A24840]. ... Hypromellose, or hydroxypropyl methylcellulose (HPMC) [L1812], is a semisynthetic, inert, and viscoelastic ... acts as a thickening agent, coating polymer, bioadhesive, solubility enhancer in solid dispersions, and …
Matched Mixtures name: … Rohto Sun and Sport …

Aluminum sulfate

Aluminum (Al), also spelled aluminum, chemical element, a lightweight, silvery-white metal of main Group 13 (IIIa, or boron group) of the periodic table . It is a chemical agent used in water purification, the pH regulation of garden soil, and other commercial or industrial applications. Medically, it is primarily used...
Approved
Matched Description: … , and tap water. ... bone and the central nervous system [L2145]. ... Aluminum (Al) is ubiquitous and represents the third most common element in the Earth’s crust. …

Entrectinib

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's...
Approved
Investigational
Matched Description: … tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and ... FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and ... This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tolvaptan

Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Approved
Matched Description: … levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and …

Rolitetracycline

A pyrrolidinylmethyl tetracycline.
Approved

Pitavastatin

Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively...
Approved
Matched Iupac: … (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid …
Matched Description: … hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid ... lipid levels and ultimately reduce the risk of cardiovascular disease. ... studies to significantly reduce the risk of development of CVD and all-cause mortality. …

Piflufolastat F 18

Prostate cancer is the most common non-cutaneous malignancy affecting men in North America - despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and location of tumor metastases and recurrences. The images generated by positron emission tomography (PET) are less detailed than those...
Approved
Investigational
Matched Iupac: … 2S)-2-({[(1S)-1-carboxy-5-{[6-(¹⁸F)fluoropyridin-3-yl]formamido}pentyl]carbamoyl}amino)pentanedioic acid …
Matched Description: … location of tumor metastases and recurrences. ... and more accurate detection of suspected prostate cancer metastases or recurrences. ... despite this, an ongoing challenge in prostate cancer therapy is the difficulty in imaging the extent and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Levoketoconazole

Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections.[A244078, A244083] Ketoconazole has been used both on- and off-label to treat...
Approved
Investigational
Matched Description: … chemistry, and opportunistic infections. ... chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and ... with accompanying changes in body composition, neuropsychiatric effects, changes in blood pressure and …
Matched Categories: … Sex Hormones and Insulins …

Apremilast

Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole.[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted...
Approved
Investigational
Matched Description: … It belongs to the same drug class as [Roflumilast] and [Crisaborole]. ... associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Lenvatinib

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular...
Approved
Investigational
Matched Description: … differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression ... 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. ... kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Olodaterol

Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and...
Approved
Matched Description: … LABAs including improved convenience and compliance and improved airflow over a 24-hour period. ... novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and ... signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and …
Matched Categories: … olodaterol and tiotropium bromide …

Lymecycline

Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections.[L13880,L13883] It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK...
Approved
Investigational
Matched Iupac: … methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]formamido}methyl)amino]-2-aminohexanoic acid …
Matched Description: … Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and ... has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and ... It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. …

Levallorphan

An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia,...
Approved

Lurbinectedin

Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate...
Approved
Investigational
Matched Description: … including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,[A214322] and ... [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed ... in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tamoxifen

Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers...
Approved
Matched Description: … treatment for these types of cancers as patients generally have better survival, side effect profiles, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Idarubicin

An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Approved
Matched Description: … The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …

Propafenone

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Approved

Cisapride

In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Approved
Investigational
Withdrawn
Matched Description: … The FDA issued a warning letter regarding this risk to health care professionals and patients. …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …

Dexamethasone acetate

Commonly known as decadron, dexamethasone acetate is a glucocorticosteroid previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions.[T797,L10695,L14348] Developed in 1957, dexamethasone is structurally similar to other corticosteroids such as hydrocortisone and prednisolone. Dexamethasone acetate has largely been replaced by dexamethasone phosphate and...
Approved
Investigational
Vet approved
Matched Description: … one-third in patients on oxygen therapy and mechanical ventilation, respectively. ... previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and ... [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues …

Teriparatide

Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in...
Approved
Investigational
Matched Description: … Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. ... [A251395] Teriparatide is used in the treatment of osteoporosis in men and women.[L42590, L42595] ... [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] …
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Parathyroid Hormones and Analogues ... Calcium-Regulating Hormones and Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Siponimod

Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to...
Approved
Investigational
Matched Iupac: … cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid …
Matched Description: … , disrupting communication between the brain and other parts of the body. ... It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. ... [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Ozenoxacin

To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients...
Approved
Investigational
Matched Iupac: … cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …
Matched Description: … has demonstrated safe and effective therapy in both the adult and pediatric population. ... pediatric patients 2 months of age and older. ... Despite being a common and highly contagious bacerial skin infection that affects millions of children …

Besifloxacin

Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Approved
Matched Iupac: … 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid …

Amisulpride

Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in...
Approved
Investigational
Matched Description: … D2 and D3 receptors. ... , and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major ... Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine …
Matched Categories: … Benzamides and benzamide derivatives …
Displaying drugs 751 - 775 of 15016 in total